Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

471 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Amsacrine combined with etoposide and methylprednisolone is a feasible and safe component in first-line intensified treatment of pediatric patients with high-risk acute lymphoblastic leukemia in CoALL08-09 trial.
Mezger K, Ebert S, Muhle HE, Stadt UZ, Borkhardt A, Dilloo D, Faber J, Feuchtinger T, Imschweiler T, Jorch N, Pekrun A, Schmid I, Schramm F, Zimmermann M, Horstmann MA, Escherich G. Mezger K, et al. Among authors: borkhardt a. Pediatr Blood Cancer. 2022 Dec;69(12):e29997. doi: 10.1002/pbc.29997. Epub 2022 Sep 21. Pediatr Blood Cancer. 2022. PMID: 36129234
Relapse, not regimen-related toxicity, was the major cause of treatment failure in 11 children with Down syndrome undergoing haematopoietic stem cell transplantation for acute leukaemia.
Meissner B, Borkhardt A, Dilloo D, Fuchs D, Friedrich W, Handgretinger R, Peters C, Schrauder A, Schuster FR, Vormoor J, Maecker B, Sykora KW, Zintl F, Welte K, Sauer M. Meissner B, et al. Among authors: borkhardt a. Bone Marrow Transplant. 2007 Nov;40(10):945-9. doi: 10.1038/sj.bmt.1705844. Epub 2007 Sep 3. Bone Marrow Transplant. 2007. PMID: 17768387
Promising therapy results for lymphoid malignancies in children with chromosomal breakage syndromes (Ataxia teleangiectasia or Nijmegen-breakage syndrome): a retrospective survey.
Bienemann K, Burkhardt B, Modlich S, Meyer U, Möricke A, Bienemann K, Mauz-Körholz C, Escherich G, Zimmermann M, Körholz D, Janka-Schaub G, Schrappe M, Reiter A, Borkhardt A. Bienemann K, et al. Among authors: borkhardt a. Br J Haematol. 2011 Nov;155(4):468-76. doi: 10.1111/j.1365-2141.2011.08863.x. Epub 2011 Sep 19. Br J Haematol. 2011. PMID: 21923652 Free article.
Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96.
Eckert C, von Stackelberg A, Seeger K, Groeneveld TW, Peters C, Klingebiel T, Borkhardt A, Schrappe M, Escherich G, Henze G. Eckert C, et al. Among authors: borkhardt a. Eur J Cancer. 2013 Apr;49(6):1346-55. doi: 10.1016/j.ejca.2012.11.010. Epub 2012 Dec 19. Eur J Cancer. 2013. PMID: 23265714
471 results